Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04231513 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess Safety, Tolerability, Pharmacokinetics (PK), Immunogenicity, and Pharmacodynamics (PD) of Intravenous Infusions of E2814 in Healthy Participants
A Phase 1 study, sponsored by Eisai.
- Completed
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
NCT04231513 is a Phase 1 study that has completed, run by Eisai. The registered enrollment target is 72 participants.
The verdict
NCT04231513, a Phase 1 study, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the safety and tolerability of single and multiple intravenous infusions of E2814 in healthy adult participants.
Interventions
- DRUG E2814
- DRUG E2814-matched placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2019-12-16 |
| Est. Completion | 2023-03-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04231513
The ClinicalTrials.gov registry entry for NCT04231513 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which E2814 is the first listed.
NCT04231513 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04231513 about?
NCT04231513 is a clinical study titled "A Study to Assess Safety, Tolerability, Pharmacokinetics (PK), Immunogenicity, and Pharmacodynamics (PD) of Intravenous Infusions of E2814 in Healthy Participants". The primary objective of this study is to evaluate the safety and tolerability of single and multiple intravenous infusions of E2814 in healthy adult participants.
What is the current status of trial NCT04231513?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2019-12-16. Estimated completion is 2023-03-09.
What interventions are being tested in trial NCT04231513?
The interventions under investigation include: E2814 (DRUG), E2814-matched placebo (DRUG).
Who is sponsoring clinical trial NCT04231513?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.